PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7883665

Computer--aided drug interaction retrieval programme.

A N Bajaj·S M Karandikar·M R Baichwal
View original source ↗Export metadata ↓

Abstract

A drug interaction database has been created to include information on drug interactions based both on the generic and trade names of drugs. The database has approximately one thousand records that provide the information on drug-drug, food, smoke, alcohol interactions and a message to briefly describe the particulars of drug interactions. The computer programme was designed using Dbase III plus commands, to readily identify potentially significant interactions in a prescription. The computer outputs may be used to alert the physicians in time to take precautions and hence to reduce the incidences of adverse effects associated with drug interactions. This would result in reduction in hospital stay as well as reducing costs of medical care. This is urgently needed in public as well as private hospitals.

Explore related subjects

Drug InteractionsHumansInformation Storage and RetrievalInformation SystemsResearch DesignSoftwareJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A N Bajaj, S M Karandikar, M R Baichwal. 1994. Computer--aided drug interaction retrieval programme.. https://pubmed.ncbi.nlm.nih.gov/7883665/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1997

Mechanisms of the inhibition of human erythrocyte pyridoxal kinase by drugs.

The aim of this study was to investigate the interaction between drugs chosen for their clinical neurotoxicity or chemical structure and vitamin B6 metabolism. After a preliminary screening of drugs to determine their potential inhibitory effect on erythrocyte nonpurified pyridoxal kinase (PLK) (EC 2.7.1.35), additional investigations, including kinetic studies and detection of chemical reactivity between the inhibiting drugs and pyridoxal (PL) or pyridoxal-5'-phosphate (PLP), using UV-visible spectrophotometry and mass analysis, were carried out to specify the mechanism of PLK inhibition. Depending on the results, the inhibiting drugs were divided into three groups. The first group included theophylline and progabide and inhibited PLK using either PL or pyridoxamine (PM) as substrate and thereby were true inhibitors. Moreover, they did not form covalent complexes with PL or PLP. The second group, which included cycloserine, dopamine, isoniazid, and thiamphenicol glycinate, inhibited PLK using PL, but not PM, as substrate. They were able to react with PL or PLP to form covalent complexes, and kinetic studies suggested that the observed PLK inhibition was due to these formed complexes. A third group, which consisted of levodopa, D-penicillamine, and muzolimine, inhibited PLK using PL, but not PM, as substrate. They formed, with PL or PLP, chemical derivatives that probably had no inhibitory effect on PLK. These results and the clinical consequences of such interactions are discussed and compared with results of previous studies.

Drug Interactions↗